Nov 2016

biocartis

Joint Bookrunner

€ 32.6 million

Accelerated Bookbuild Offering

Biocartis

Biocartis is an innovative commercial stage molecular diagnostics company providing next generation diagnostic solutions.

Accelerated bookbuild offering amounting to €32.7m.
Proceeds will be used to finance further clinical trials, to support the global roll-out of its products and to fund the expansion of manufacturing capacity.
Kempen & Co acted as Joint Bookrunner in the transaction.